HIF1A and colon adenocarcinoma: It is noteworthy to highlight that large, established metastases selectively upregulated HIF‐1α upon MTD therapies independently of primary cell‐type [i.e., HT29 (colon) versus EMT6‐CDDP (breast)], secondary location (i.e., liver versus lung), and chemotherapeutic drug context (i.e., neoadjuvant versus adjuvant therapies), whereas HIF‐2α was induced only in small nodules, as observed in the colonic adenocarcinoma model.